Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4794465 | 0.89 | L3MBTL1 (0.50) | CYP19A1L3MBTL1RAB9ANPC1ALDH1A1 | |
| SCHEMBL16050432 | 0.84 | CYP19A1 (0.59) | CYP19A1L3MBTL1ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL16050449 | 0.84 | LTA4H (0.44) | CYP19A1TSHR | |
| SCHEMBL15653896 | 0.82 | SIGMAR1 (0.47) | CYP19A1L3MBTL1SIGMAR1NPC1SMN1; SMN2 | |
| SCHEMBL16050368 | 0.82 | KDM4E (0.43) | CYP19A1L3MBTL1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL16050737 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL4794171 | 0.80 | RAB9A (0.42) | CYP19A1L3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4795010 | 0.80 | LMNA (0.49) | CYP19A1RAB9ANPC1ALDH1A1POLB | |
| SCHEMBL15652147 | 0.80 | HRH3 (0.44) | L3MBTL1SIGMAR1RAB9ANPC1POLB | |
| SCHEMBL15652608 | 0.80 | ALDH1A1 (0.49) | L3MBTL1ALDH1A1CYP1A2CYP2D6CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | claimed |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | claimed |
| US-20230192680-A1 | NEW AGENT FOR PROMOTING PHOSPHORYLATION OF eIF2a | ER STRESS RESEARCH INSTITUTE, INC. (JP) | 2023-06-22 | — | — | US | claimed |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | claimed |
| WO-2022261160-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2022-12-15 | — | — | WO | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-30 | — | — | US | claimed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | claimed |
| WO-2020184578-A1 | NOVEL elF2α PHOSPHORYLATION PROMOTER | 小胞体ストレス研究所株式会社 | 2020-09-17 | — | — | WO | claimed |
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | claimed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | claimed |
| EP-1742944-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2006001894-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICAL CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICAL CORPORATION | 2005-11-10 | — | — | US | claimed |
| EP-1414837-B1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS INC (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040116376-A1 | Adenosine A3 receptor agonists | CV THERAPEUTICS, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1414837-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030078232-A1 | Adenosine receptor A3 agonists | CV THERAPEUTICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2003014137-A1 | ADENOSINE A3 RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2003-02-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078232-A1 | Adenosine receptor A3 agonists | ADORA3, ADORA2A, ADORA1 | CYP19A1 3376/4885L3MBTL1 1597/4885SIGMAR1 1237/4885 |
| US-10959986-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | CYP19A1 588/4885L3MBTL1 3787/4885SIGMAR1 3303/4885 |
| US-20230192680-A1 | NEW AGENT FOR PROMOTING PHOSPHORYLATION OF eIF2a | EIF2A, EIF2AK1, EIF2AK4 | CYP19A1 3538/4885L3MBTL1 1529/4885SIGMAR1 753/4885 |
| US-20050250808-A1 | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | CYP19A1 2876/4885L3MBTL1 3107/4885SIGMAR1 454/4885 |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | NISCH, TK2, FDPS | CYP19A1 4450/4885L3MBTL1 2337/4885SIGMAR1 3883/4885 |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | CYP19A1 474/4885L3MBTL1 3254/4885SIGMAR1 4689/4885 |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | CYP19A1 474/4885L3MBTL1 3254/4885SIGMAR1 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.